Nearly 1 million Part D enrollees took Mounjaro, approved in 2022 for type 2 diabetes, up from 54,000 in 2022
Why Am I Tired on Semaglutide
Metabolic Rate Effects: Some research suggests GIP may influence energy expenditure, though this is still being studied
A healthy diet and regular exercise are vital for long-term weight loss success
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Case Rep Dermatol